Ionis Pharmaceuticals

We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy. 

Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
Company Growth (employees)
Type
Public
HQ
Carlsbad, US
Founded
1989
Size (employees)
435 (est)
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US

Key People at Ionis Pharmaceuticals

Stanley Crooke

Stanley Crooke

CEO
Lynne Parshall

Lynne Parshall

COO / CFO
Elizabeth Hougen

Elizabeth Hougen

Chief Accounting Officer
C. Frank Bennett

C. Frank Bennett

Senior Vice President of Research
Sarah Boyce

Sarah Boyce

CBO
Steve Hughes

Steve Hughes

Chief Clinical Development Officer
Brett P. Monia

Brett P. Monia

Senior Vice President of Antisense Drug Discovery

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct

Ionis Pharmaceuticals Data and Metrics

Ionis Pharmaceuticals Financial Metrics

Ionis Pharmaceuticals's revenue was reported to be $110.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

110.3 m

Net income (Q1, 2017)

3.5 m

EBIT (Q1, 2017)

14 m

Market capitalization (22-Sep-2017)

6.4 b

Closing share price (22-Sep-2017)

51.8

Cash (31-Mar-2017)

114.2 m
Ionis Pharmaceuticals's current market capitalization is $6.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

147.3 m214.2 m283.7 m346.6 m

Revenue growth, %

45%32%22%

General and administrative expense

48.6 m

Operating expense total

48.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

57.1 m44.1 m62.6 m120.4 m49.1 m36.9 m38.5 m110.9 m110.3 m

General and administrative expense

4.5 m4.5 m7.5 m7.8 m8.8 m10.6 m9.8 m10.2 m13.7 m

Operating expense total

4.5 m4.5 m7.5 m7.8 m8.8 m10.6 m9.8 m10.2 m13.7 m

EBIT

(6.7 m)(21.5 m)(9.3 m)44.6 m(48.1 m)(54.7 m)(48.9 m)16.1 m14 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

160 m143 m128.8 m84.7 m

Accounts Receivable

51.1 m

Inventories

8 m6.3 m6.9 m7.5 m

Current Assets

735.5 m836.6 m837 m797.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

94.1 m73.2 m148.3 m119.5 m126.6 m93.3 m112.5 m84.3 m114.2 m

Inventories

7.8 m7.1 m6.8 m6.8 m6.6 m6.5 m7.7 m9.3 m6.8 m

Current Assets

705.8 m681.2 m835.4 m855.5 m868.3 m763.9 m698 m730.3 m962.4 m

PP&E

86.3 m88.1 m89 m89.7 m89.2 m90.4 m90.6 m91 m95.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(60.6 m)(39 m)(88.3 m)(86.6 m)

Depreciation and Amortization

6.6 m6.4 m7 m7.5 m

Inventories

(1.9 m)1.7 m(609 k)(590 k)

Accounts Payable

66 k4.8 m9.2 m(10.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12.1 m)(26.7 m)(16.7 m)35.6 m(35.8 m)(62.9 m)(56.9 m)7.4 m3.5 m

Inventories

7.8 m7.1 m6.8 m6.8 m6.6 m6.5 m7.7 m9.3 m6.8 m

Accounts Payable

13.5 m15.6 m16.5 m11 m19.3 m19.5 m17.6 m15.7 m23.2 m
USDY, 2017

Revenue/Employee

253.6 k

Financial Leverage

5.4 x
Show all financial metrics

Ionis Pharmaceuticals Market Value History

Traffic Overview of Ionis Pharmaceuticals

Ionis Pharmaceuticals Online and Social Media Presence

Ionis Pharmaceuticals News and Updates

Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval

Spinraza, a “life-changing” drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that.

Stocks turn lower as oil prices continue to skid

U.S. stocks are slipping Monday afternoon as the price of oil continues to dive and energy companies take large losses. The strong dollar is again rippling through the market, pushing oil prices lower and pressuring energy and mining stocks. U.S. crude reached its lowest price in almost four mon…

Wall St. Moves Higher, Though Energy Stocks Keep Sliding

Tesla Motors agreed to buy the solar panel maker SolarCity for $2.6 billion in stock in a merger aimed at creating a one-stop shop for cleaner energy.

BRIEF-Ionis Pharmaceuticals licenses oral antisense drug to Janssen

* Ionis Pharmaceuticals licenses first oral antisense drug acting locally in the GI tract to Janssen

Ionis Pharmaceuticals Company Life and Culture

You may also be interested in